A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant Glioma

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220811

Enrollment

Registered

2009-08-14

Start date

2009-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant glioma

Interventions

investigational material(s) Generic name etc : R435(Bevacizumab) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Age >= 20 years -Histologically confirmed malignant glioma -All patients must have received prior temozolomide and prior radiation therapy for malignant glioma. -No evidence of recent hemorrhage on baseline MRI of the brain. -Karnofsky Performance Status >= 70%

Exclusion criteria

Exclusion criteria: -The patient has received more than two regimens for malignant glioma. -History of hemoptysis(>=Grade2) within 1 month before randomization. -Serious non-healing wound or untreated bone fracture.

Design outcomes

Primary

Measure	Time frame
6-month progression free survival	—

Secondary

Measure	Time frame
1-year survival rate, Progression free survival, Overall response rate, Overall survival, Disease control rate	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026